Dr. Deliang Guo's lab at Ohio State University focuses on finding new treatment strategies for glioblastoma (GBM), an aggressive brain tumor. The research explores how GBM cells utilize lipids and glutamine for growth and survival, aiming to disrupt these processes to develop effective therapies. By studying lipid metabolism and testing new drug combinations, the lab hopes to identify safer and more effective ways to treat this challenging disease.

Dr. Nicholas C. Denko's lab focuses on improving treatments for non-small cell lung cancer (NSCLC) by addressing the challenge of tumor hypoxia. They explore how reducing oxygen demand in tumors can enhance the effects of existing therapies like radiation and immunotherapy. The lab investigates novel derivatives of papaverine, an FDA-approved drug, to assess their potential in overcoming resistance to these treatments.

Dr. Monica Venere's lab focuses on understanding a specific type of brain tumor called ependymoma, particularly those driven by the ZFTA-RELA fusion. These tumors are especially challenging to treat, and the lab is investigating a protein called FACT that is involved in maintaining the cancerous state of these tumors. By exploring how FACT contributes to tumor growth and its potential as a drug target, the lab aims to develop new therapies that could significantly improve patient outcomes.